European Journal of Clinical Microbiology

, Volume 4, Issue 2, pp 144–145 | Cite as

Interpretive standards of cefbuperazone disk diffusion susceptibility tests

  • A. L. Barry
  • R. N. Jones
  • C. Thornsberry


Internal Medicine Susceptibility Test Disk Diffusion Disk Diffusion Susceptibility Diffusion Susceptibility Test 


  1. 1.
    Kumano, K., Mikami, H., Inoue, M., Mitsuhashi, S.: In vitro and in vivo antibacterial activity of T-1982. Chemotherapy 1982, 30, Supplement: 1–19.Google Scholar
  2. 2.
    Tai, M., Fukuoka, Y., Yotsuji, A., Kumano, K., Takahata, M., Mikami, H., Yasuda, T., Saikawa, I., Mitsuhashi, S.: In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic. Antimicrobial Agents and Chemotherapy 1982, 22: 724–728.Google Scholar
  3. 3.
    Khan, N. J., Bihl, J. A., Schell, R. F., LeFrock, J. L., Weber, S. J.: Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins. Antimicrobial Agents and Chemotherapy 1984, 26: 585–590.PubMedGoogle Scholar
  4. 4.
    National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved Standard M2-A3. NCCLS, Villanova, PA, 1984.Google Scholar
  5. 5.
    National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility tests for bacteria that grows aerobically. Tentative standard M7-T. NCCLS, Villanova, PA, 1982.Google Scholar

Copyright information

© Vieweg Publishing 1985

Authors and Affiliations

  • A. L. Barry
    • 1
  • R. N. Jones
    • 2
  • C. Thornsberry
    • 3
  1. 1.Clinical Microbiology InstituteTualatinUSA
  2. 2.Kaiser-Permanente Regional LaboratoryClackamasUSA
  3. 3.Centers for Disease ControlAtlantaUSA

Personalised recommendations